Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verrica Pharmaceuticals Inc VRCA

Healthcare
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential... see more

Recent & Breaking News (NDAQ:VRCA)

Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference

GlobeNewswire February 23, 2021

Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

GlobeNewswire February 17, 2021

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

GlobeNewswire January 19, 2021

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

GlobeNewswire December 23, 2020

Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum

GlobeNewswire November 17, 2020

Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference

GlobeNewswire November 12, 2020

Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)

GlobeNewswire November 10, 2020

Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results

GlobeNewswire November 9, 2020

JAMA Dermatology Publishes Results from Verrica's Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials

GlobeNewswire September 23, 2020

Novan Inc. and Verrica Pharmaceuticals Participate in Virtual Panel to Discuss Developing Treatments for Molluscum Contagiosum on SNN Network

Accesswire September 22, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

PR Newswire September 14, 2020

VRCA Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Verrica Pharmaceuticals Inc. and Lead Plaintiff Deadline: September 14, 2020

ACCESSWIRE IA September 14, 2020

FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 14, 2020

VRCA Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Verrica Pharmaceuticals Inc. and Lead Plaintiff Deadline: September 14, 2020

PR Newswire September 14, 2020

DEADLINE TODAY: The Schall Law Firm Announces It Is Investigating Claims Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Business Wire September 14, 2020

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 14, 2020

VRCA Class Action Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

ACCESSWIRE IA September 13, 2020

FINAL DEADLINE NEXT WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA September 11, 2020

VRCA Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Verrica Pharmaceuticals Inc. and Lead Plaintiff Deadline: September 14, 2020

ACCESSWIRE IA September 11, 2020

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)

Business Wire September 11, 2020